Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of A...
Artiva Biotherapeutics, Inc. (ARTV)
Company Research
Source: GlobeNewswire
SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings) from February 4 – 7, 2026, in Salt Lake City, Utah highlighting the cost-effectiveness of AlloNK in a community rheumatology practice and continued durability of AlloNK in Non-Hodgkin Lymphoma (NHL). The following abstracts will be presented as poster presentations at the 2026 Tandem Meetings: Poster ID: 440AB-101, an Off-the-Shelf NK Cell Therapy Administered in an Outpatient Community Rheumatology Practice, Is More Cost-Effective Than CAR-T Treatments for Rheumatologic DiseasesPoster Session:Health Services and Barriers to AccessDate / Time: Thursday, February 5, 2026, at 6:30 pm MSTAutho
Show less
Read more
Impact Snapshot
Event Time:
ARTV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARTV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARTV alerts
High impacting Artiva Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ARTV
News
- Artiva Biotherapeutics (ARTV) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $18.00 price target on the stock.MarketBeat
- Artiva Biotherapeutics GAAP EPS of -$3.43 [Seeking Alpha]Seeking Alpha
- Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights [Yahoo! Finance]Yahoo! Finance
- Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business HighlightsGlobeNewswire
- Artiva Biotherapeutics Pivots to Rheumatoid Arthritis at TD Cowen, Teases 2026 RA Data Update [Yahoo! Finance]Yahoo! Finance
ARTV
Sec Filings
- 3/10/26 - Form 4
- 3/10/26 - Form S-8
- 3/10/26 - Form 10-K
- ARTV's page on the SEC website